Pfizer is looking to follow its vaccine/oral antiviral combination that has proved so profitable in COVID-19 with a similar approach in respiratory syncytial virus (RSV). The drugmaker is in the ...

Pfizer has bolstered the evidence behind its respiratory syncytial virus (RSV) vaccine with a positive trial of the shot used to protect newborns, adding to earlier results in older adults. The ...

Pfizer’s (NYSE:PFE) respiratory syncytial virus (RSV) vaccine Abrysvo was well-tolerated and generated strong neutralizing ...

Pfizer has reported top-line results from the Phase III RENOIR clinical trial of its respiratory syncytial virus (RSV) vaccine, ABRYSVO, for RSV-linked lower respiratory tract disease (LRTD).

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely in the past.”  | The company benefited from higher-than-expected sales of ...

GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing a rare neurological disorder, the U.S. Food Drug Administration said on ...

Drug company Pfizer is seeking to expand the approval of its respiratory syncytial virus (RSV) vaccine to include adults over the age of 18.

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

GSK has been the dominant player in the RSV vaccine market since Arexvy first gained approval in 2023, although Pfizer has made inroads into its market share. While initial launches for both ...